|
1
|
Seiki M, Ueki S, Tanaka Y, Soeda M, Hori
Y, Aita H, Yoneta T, Morita H, Tagashira E and Okabe S: Studies on
anti-ulcer effects of a new compound, zinc l-carnosine (z-103).
Nihon Yakurigaku Zasshi. 95:257–269. 1990.PubMed/NCBI View Article : Google Scholar : (In Japanese).
|
|
2
|
Tan B, Luo HQ, Xu H, Lv NH, Shi RH, Luo
HS, Li JS, Ren JL, Zou YY, Li YQ, et al: Polaprezinc combined with
clarithromycin-based triple therapy for Helicobacter
pylori-associated gastritis: A prospective, multicenter, randomized
clinical trial. PLoS One. 12(e0175625)2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wada I, Otaka M, Jin M, Odashima M,
Komatsu K, Konishi N, Matsuhashi T, Horikawa Y, Ohba R, Itoh H and
Watanabe S: Expression of HSP72 in the gastric mucosa is regulated
by gastric acid in rats-Correlation of HSP72 expression with
mucosal protection. Biochem Biophys Res Commun. 349:611–618.
2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Qin Y, Naito Y, Handa O, Hayashi N, Kuki
A, Mizushima K, Omatsu T, Tanimura Y, Morita M, Adachi S, et al:
Heat shock protein 70-dependent protective effect of polaprezinc on
acetylsalicylic acid-induced apoptosis of rat intestinal epithelial
cells. J Clin Biochem Nutr. 49:174–181. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ohkawara T, Nishihira J, Nagashima R,
Takeda H and Asaka M: Polaprezinc protects human colon cells from
oxidative injury induced by hydrogen peroxide: Relevant to
cytoprotective heat shock proteins. World J Gastroenterol.
12:6178–6181. 2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ueda K, Ueyama T, Oka M, Ito T, Tsuruo Y
and Ichinose M: Polaprezinc (Zinc L-Carnosine) is a potent inducer
of anti-oxidative stress enzyme, Heme Oxygenase (HO)-1-a new
mechanism of gastric mucosal protection. Pharmacol Sci.
110:285–294. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Omatsu T, Naito Y, Handa O, Mizushima K,
Hayashi N, Qin Y, Harusato A, Hirata I, Kishimoto E, Okada H, et
al: Reactive oxygen species-quenching and anti-apoptotic effect of
polaprezinc on indomethacin-induced small intestinal epithelial
cell injury. J Gastroenterol. 45:692–702. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Shimada T, Watanabe N, Ohtsuka Y, Endoh M,
Kojima K, Hiraishi H and Terano A: Polaprezinc Down-regulates
proinflammatory cytokine-induced nuclear Factor-kappaB activation
and Interleukin-8 expression in gastric epithelial cells. J
Pharmacol Exp Ther. 291:345–352. 1999.PubMed/NCBI
|
|
9
|
Handa O, Yoshida N, Tanaka Y, Ueda M and
Yoshikawa T: Inhibitory effect of polaprezinc on the inflammatory
response to Helicobacter pylori. Can J Gastroenterol. 16:785–789.
2002.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ohata S, Moriyama C, Yamashita A, Nishida
T, Kusumoto C, Mochida S, Minami Y, Nakada J, Shomori K, Inagaki Y,
et al: Polaprezinc protects mice against endotoxin shock. J Clin
Biochem Nutr. 46:234–243. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Watanabe S, Wang XE, Hirose M, Kivilioto
T, Osada T, Miwa H, Oide H, Kitamura T, Yoneta T and Seto K:
Insulin-like growth factor I Plays a role in gastric wound healing:
Evidence using a zinc derivative, polaprezinc, and an in vitro
rabbit wound repair model. Aliment Pharmacol Ther. 12:1131–1138.
1998.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Seto K, Yoneta T, Suda H and Tamaki H:
Effect of polaprezinc (N-(3-aminopropionyl)-L-histidinato zinc), a
novel antiulcer agent containing zinc, on cellular proliferation:
Role of insulin-like growth factor I. Biochem Pharmacol.
58:245–250. 1999.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Jung DH, Park JC, Lee YC, Lee SK, Shin SK,
Chung H, Park JJ, Kim JH, Youn YH and Park H: Comparison of the
efficacy of Polaprezinc plus proton pump inhibitor and rebamipide
plus proton pump inhibitor treatments for endoscopic submucosal
dissection-induced ulcers. Clin Gastroenterol. 55:233–238.
2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kono T, Asama T, Chisato N, Ebisawa Y,
Okayama T, Imai K, Karasaki H, Furukawa H and Yoneda M: Polaprezinc
prevents ongoing thioacetamide-induced liver fibrosis in rats. Life
Sci. 90:122–130. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Katayama S, Nishizawa K, Hirano M,
Yamamura S and Momose Y: Effect of polaprezinc on healing of acetic
acid-induced stomatitis in hamsters. J Pharm Pharm Sci. 3:114–117.
2000.PubMed/NCBI
|
|
16
|
Liu Z, Xie W, Li M, Teng N, Liang X, Zhang
Z, Yang Z and Wang X: Oral administration of polaprezinc attenuates
fluorouracil induced intestinal mucositis in a mouse model. Basic
Clin Pharmacol Toxicol. 121:480–486. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Liu ZY, Xie WB, Li MR, Teng N, Liang X and
Zhang ZQ: Effects of polaprezinc on gastric mucosal damage and
neurotransmitters in a rat model of chemotherapy-induced vomiting.
Int Med Res. 46:2436–2444. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Liu ZY, Xie WB, Li MR, Liu J, Liang X and
Li T: Intrarectally administered polaprezinc attenuates the
development of dextran sodium sulfate-induced ulcerative colitis in
mice. Exp Ther Med. 18:4927–4934. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kashimura H, Suzuki K, Hassan M, Ikezawa
K, Sawahata T, Watanabe T, Nakahara A, Mutoh H and Tanaka N:
Polaprezinc, a mucosal protective agent, in combination with
lansoprazole, amoxicillin and clarithromycin increases the cure
rate of Helicobacter pylori infection. Aliment Pharmacol Ther.
13:483–487. 1999.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nishizawa T, Suzuki H, Kanai T and Yahagi
N: Proton pump inhibitor alone vs proton pump inhibitor plus
mucosal protective agents for endoscopic submucosal
dissection-induced ulcer: A systematic review and meta-analysis. J
Clin Biochem Nutr. 56:85–90. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Matsukura T and Tanaka H: Applicability of
zinc complex of L-carnosine for medical use. Biochemistry (Mosc).
65:817–823. 2000.PubMed/NCBI
|
|
22
|
Matsuda K, Mera Y, Wada H, Aruga H, Saik Y
and Taniguchi Y: Repeated dose toxicity studies on
catena-(S)-[mu-[N alpha-(3-aminopropionyl)
histidinato(2-)-N1,N2,O:N tau]-zinc] in rats.
Arzneimittelforschung. 41(1036)1991.PubMed/NCBI
|
|
23
|
Furuta S, Toyama S, Miwa M and Sano H:
Disposition of polaprezinc (zinc L-carnosine complex) in rat
gastrointestinal tract and effect of cimetidine on its adhesion to
gastric tissues. J Pharm Pharmacol. 47:632–636. 1995.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Choi HS, Lim JY, Chun HJ, Lee M, Kim ES,
Keum B, Seo YS, Jeen YT, Um SH, Lee HS, et al: The effect of
polaprezinc on gastric mucosal protection in rats with ethanol
induced gastric mucosal damage: Comparison study with rebamipide.
Life Sci. 93:69–77. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Fujii Y, Matsura T, Kai M, Kawasaki H and
Yamada K: Protection by polaprezinc, an anti-ulcer drug, against
indomethacin-induced apoptosis in rat gastric mucosal cells. Jpn J
Pharmacol. 84:63–70. 2000.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yakoob J, Abbas Z, Jafri W, Usman MW and
Awan S: Zinc chloride inhibits Helicobacter pylori growth and
reduces expression of interleukin-1beta by gastric epithelial
cells. Br J Biomed Sci. 71:43–45. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ishihara R, Iishi H, Sakai N, Yano H, Uedo
N, Narahara H, Iseki K, Mikuni T, Ishiguro S and Tatsuta M:
Polaprezinc attenuates Helicobacter pylori-associated gastritis in
Mongolian gerbils. Helicobacter. 7:384–389. 2010.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Naito Y, Yoshikawa T, Yagi N, Matsuyama K,
Yoshida N, Seto K and Yoneta T: Effects of polaprezinc on lipid
peroxidation, neutrophil accumulation, and TNF-alpha expression in
rats with aspirin-induced gastric mucosal injury. Dig Dis Sci.
46:845–851. 2001.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Aita H, Yoneta T, Seto K, Morit H, Hori Y,
Takemasa T, Chaki K, Yamada H, Seiki M and Tagashira E: Studies on
the healing promoting action of Z-103 in chronic gastric ulcer
models of rats. Nihon Yakurigaku Zasshi. 99:345–352.
1992.PubMed/NCBI View Article : Google Scholar : (In Japanese).
|
|
30
|
Odashima M, Otaka M, Jin M, Wada I,
Horikawa Y, Matsuhashi T, Ohba R, Hatakeyama N, Oyake J and
Watanabe S: Zinc L-carnosine protects colonic mucosal injury
through induction of heat shock protein 72 and suppression of
NF-kappaB activation. Life Sci. 79:2245–2250. 2006.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ko JK and Leung CC: Ginger extract and
polaprezinc exert gastroprotective actions by anti-oxidant and
growth factor modulating effects in rats. J Gastroenterol Hepatol.
25:1861–1869. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Matsuoka S, Matsumura H, Nakamura H,
Oshiro S, Arakawa Y, Hayashi J, Sekine N, Nirei K, Yamagami H,
Ogawa M, et al: Zinc supplementation improves the outcome of
chronic hepatitis C and liver cirrhosis. J Clin Biochem Nutr.
45:292–303. 2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ye J, Zhang ZS, Zhu L, Lu FM, Li Y, Zhou
JJ, Lu XL and Du Q: Polaprezinc inhibits liver fibrosis and
proliferation in hepatocellular carcinoma. Mol Med Rep.
16:5523–5528. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Matsumura H, Nirei K, Nakamura H, Arakawa
Y, Higuchi T, Hayashi J, Yamagami H, Matsuoka S, Ogawa M, Nakajima
N, et al: Zinc supplementation therapy improves the outcome of
patients with chronic hepatitis C. J Clin Biochem Nutr. 51:178–184.
2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Amin M, Iqbal MS, Hughes RW, Khan SA,
Reynolds PA, Enne VI, Sajjad-ur-Rahman and Mirza AS:
Mechanochemical synthesis and in vitro anti-Helicobacter pylori and
uresase inhibitory activities of novel zinc(II)-famotidine complex.
J Enzyme Inhib Med Chem. 25:383–390. 2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Nishizawa T and Yahagi N: Endoscopic
mucosal resection and endoscopic submucosal dissection: Technique
and new directions. Curr Opin Gastroenterol. 33:315–319.
2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Inaba T, Ishikawa S, Toyokawa T, Ishikawa
H, Miyahara K, Wato M, Kawai K, Okada H and Yamamoto K: Basal
protrusion of ulcers induced by endoscopic submucosal dissection
(ESD) during treatment with proton pump inhibitors, and the
suppressive effects of polaprezinc. Hepatogastroenterology.
57:678–684. 2010.PubMed/NCBI
|
|
38
|
Watari I, Oka S, Tanaka S, Aoyama T,
Imagawa H, Shishido T, Yoshida S and Chayama K: Effectiveness of
polaprezinc for low-dose aspirin-induced small-bowel mucosal
injuries as evaluated by capsule endoscopy: A pilot randomized
controlled study. Gastroenterology. 13(108)2013.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Doi H, Fujiwara M, Suzuki H, Niwa Y,
Nakayama M, Shikata T, Odawara S, Takada Y, Kimura T, Kamikonya N
and Hirota S: Polaprezinc reduces the severity of radiation-induced
mucositis in head and neck cancer patients. Mol Clin Oncol.
3:381–386. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Hayashi H, Kobayashi R, Suzuki A, Ishihara
M, Nakamura N, Kitagawa J, Kanemura N, Kasahara S, Kitaichi K, Hara
T, et al: Polaprezinc prevents oral mucositis in patients treated
with high-dose chemotherapy followed by hematopoietic stem cell
transplantation. Anticancer Res. 34:7271–7277. 2014.PubMed/NCBI
|
|
41
|
Ishihama H, Sayo S, Yokoyama T, Ueno M,
Ebihara N, Doi Y, Asano K, Kawamata H, Imai H and Ueki K:
P1-032preventive and therapeutic effects of Polaprezinc suspension
on oral mucosal injury. Ann Oncol. 24:ix66–ix99. 2013.
|
|
42
|
Hayashi H, Kobayashi R, Suzuki A, Yamada
Y, Ishida M, Shakui T, Kitagawa J, Hayashi H, Sugiyama T, Takeuchi
H, et al: Preparation and clinical evaluation of a novel lozenge
containing polaprezinc, a zinc-L-carnosine, for prevention of oral
mucositis in patients with hematological cancer who received
high-dose chemotherapy. Med Oncol. 33(91)2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Masayuki F, Norihiko K, Keita T, Miwa I,
Masayuki I, Toshihiko I, Hiromi F, Chikaaki M and Norio N: Efficacy
and safety of polaprezinc as a preventive drug for
radiation-induced stomatitis. Nihon Igaku Hoshasen Gakkai Zasshi.
62:144–150. 2002.PubMed/NCBI(In Japanese).
|
|
44
|
Doi H, Kamikonya N, Takada Y, Fujiwara M,
Tsuboi K, Inoue H, Tanooka M, Nakamura T, Shikata T, Tsujimura T
and Hirota S: Efficacy of Polaprezinc for acute radiation Proctitis
in a rat model. Int J Radiat Oncol Biol Phys. 80:877–884.
2011.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Odawara S, Doi H, Shikata T, Kitajima K,
Suzuki H, Niwa Y, Kosaka K, Tarutani K, Tsujimura T, Kamikonya N
and Hirota S: Polaprezinc protects normal intestinal epithelium
against exposure to ionizing radiation in mice. Mol Clin Oncol.
5:337–381. 2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Itagaki M, Saruta M, Saijo H, Mitobe J,
Arihiro S, Matsuoka M, Kato T, Ikegami M and Tajiri H: Efficacy of
zinc-carnosine chelate compound, Polaprezinc, enemas in patients
with ulcerative colitis. Scand J Gastroenterol. 49:164–172.
2014.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Zhang Y, Okamura S, Kudo T, Masuo T and
Mori M: Calcineurin inhibition by polaprezinc in rats with
experimentally-induced colitis. Life Sci. 88:432–439.
2011.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Hewlings S and Kalman D: A review of
Zinc-L-Carnosine and its positive effects on oral Mucositis, taste
disorders, and gastrointestinal disorders. Nutrients.
12(665)2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Takaoka T, Sarukura N, Ueda C, Kitamura Y,
Kalubi B, Toda N, Abe K, Yamamoto S and Takeda N: Effects of zinc
supplementation on serum zinc concentration and ratio of
apo/holo-activities of angiotensin converting enzyme in patients
with taste impairment. Auris Nasus Larynx. 37:190–194.
2010.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Mizukami Y, Sato J, Nihei S, Kashiwaba M,
Kudo K, Okuyama H and Tamura K: The effectiveness of Polaprezinc
preparation for taste alteration in cancer chemotherapy. Gan To
Kagaku Ryoho. 43:979–983. 2016.PubMed/NCBI(In Japanese).
|
|
51
|
Sakagami M, Ikeda M, Tomita H, Ikui A,
Aiba T, Takeda N, Inokuchi A, Kurono Y, Nakashima M, Shibasaki Y
and Yotsuya O: A zinc-containing compound, Polaprezinc, is
effective for patients with taste disorders: Randomized,
double-blind, placebo-controlled, multi-center study. Acta
Otolaryngol. 129:1115–1120. 2009.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Kimura K, Nakano Y, Sugizaki T, Shimoda M,
Kobayashi N, Kawahara M and Tanaka KI: Protective effect of
polaprezinc on cadmium-induced injury of lung epithelium.
Metallomics. 11:1310–1320. 2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Japan standard commodity classification
No. 872329: 11, 2009. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/2329027.
|
